1
|
Zhou Z, Mo S, Gu R, Dai W, Zou X, Han L, Zhang L, Wang R, Cai G. Hematopoietic Gene Expression Regulation Through m 6A Methylation Predicts Prognosis in Stage III Colorectal Cancer. Front Oncol 2020; 10:572708. [PMID: 33102231 PMCID: PMC7556240 DOI: 10.3389/fonc.2020.572708] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Accepted: 09/08/2020] [Indexed: 11/13/2022] Open
Abstract
Background Methylation of N6 adenosine (m6A) plays important regulatory roles in diverse biological processes. The purpose of this research was to explore the potential mechanism of m6A modification level on the clinical outcome of stage III colorectal cancer (CRC). Methods Gene set variation analysis (GSVA) and gene set enrichment analysis (GSEA) were adopted to reveal the signal pathway which was most likely affected by m6A methylation. The linear models for microarray data (LIMMA) method and the least absolute shrink-age and selection operator (LASSO) Cox regression model were used to identify the signature. The signature can sensitively separate the patients into high and low risk indicating the relapse-free survival (RFS) time based on time-dependent receiver operating characteristic (ROC) analysis. Then, the multi-gene signature was validated in GSE14333 and the Cancer Genome Atlas (TCGA) cohort. The number of the samples in GSE14333 and TCGA cohort are 63 and 150. Finally, two nomograms were set up and validated to predict prognosis of patients with stage III CRC. Results The hematopoietic cell lineage (HCL) signaling pathway was disclosed through GSEA and GSVA. Seven HCL-related genes were determined in the LASSO model to construct signature, with AUC 0.663, 0.708, and 0.703 at 1-, 3-, and 5-year RFS, respectively. Independent datasets analysis and stratification analysis indicated that the HCL-related signature was reliable in distinguishing high- and low-risk stage III CRC patients. Two nomograms incorporating the signature and pathological N stage were set up, which yielded good discrimination and calibration in the predictions of prognosis for stage III CRC patients. Conclusions A novel HCL-related signature was developed as a predictive model for survival rate of stage III CRC patients. Nomograms based on the signature were advantageous to facilitate personalized counseling and treatment in stage III CRC.
Collapse
Affiliation(s)
- Zheng Zhou
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Shaobo Mo
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Ruiqi Gu
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Weixing Dai
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Xinhui Zou
- School of Public Health, Shanghai Medical College, Fudan University, Shanghai, China
| | - Lingyu Han
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Long Zhang
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Cancer Institute, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China
| | - Renjie Wang
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| | - Guoxiang Cai
- Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China
| |
Collapse
|
2
|
Nie L, Ma R, Yuan X, Jiang L, Yang S, Xu H, Liu X, Liu Y, Zhang L, Zhu Z. The prognostic value of CD2, CD4, and HLA-DR expression and FLT3-ITD mutation in adult acute promyelocytic leukemia. Leuk Lymphoma 2020; 61:2482-2487. [PMID: 32476519 DOI: 10.1080/10428194.2020.1768386] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
In order to explore the prognostic value of CD2, CD4, and human leucocyte antigen-DR (HLA-DR) expression and Fms-like tyrosine kinase 3-internal tandem duplication (FLT3-ITD) mutation in leukemia cells in the bone marrow of patients with acute promyelocytic leukemia (APL), we retrospectively collected and analyzed the immunophenotype, molecular features and clinical characteristics of 219 newly diagnosed adult patients with APL in Henan Provincial People's Hospital from January 2010 to December 2019. It turned out that the relapse rates of patients with CD2, CD4, or HLA-DR expression and the early mortality rates of patients with CD2 expression, HLA-DR expression, or FLT3-ITD mutation were higher than those of their counterparts. Moreover, reduced overall survival was found for patients who showed CD2 expression, HLA-DR expression or FLT3-ITD mutation. Therefore, CD2 expression, HLA-DR expression and FLT3-ITD mutation were adverse prognostic factors in adults with APL.
Collapse
Affiliation(s)
- Lu Nie
- Zhengzhou University, Zhengzhou, China.,Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.,Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Rongjun Ma
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Xiaoli Yuan
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Li Jiang
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Shiwei Yang
- Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Hui Xu
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Xiaoyin Liu
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Yuanbo Liu
- Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Lin Zhang
- Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China
| | - Zunmin Zhu
- Zhengzhou University, Zhengzhou, China.,Department of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.,Institute of Hematology, Henan Provincial People's Hospital, Zhengzhou, China.,Henan Key Laboratory of Stem Cell Differentiation and Modification, Zhengzhou, China
| |
Collapse
|
3
|
Mendoza AS, Qing X, Dungo M, Lasky J, Panosyan E, Cai J. HLA-DR antigen-positive acute promyelocytic leukemia. Exp Mol Pathol 2016; 101:197-200. [PMID: 27544027 DOI: 10.1016/j.yexmp.2016.07.013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2016] [Accepted: 07/09/2016] [Indexed: 10/21/2022]
Abstract
Acute promyelocytic leukemia (APL) with t(15;17)(q22;q21)/PML-RARα is a subtype of acute myeloid leukemia (AML) with distinct morphologic and immunophenotypic characteristics. It is a highly aggressive disease that requires rapid diagnosis and early intervention. In addition to morphologic evaluation, flow cytometry has been widely used to facilitate prompt diagnosis of this disease. Compared with other types of AML, APL typically displays a triad of absent or weak CD34, absent HLA-DR, and positive CD117. HLA-DR positive APL is extremely rare and its clinical and pathological features have not been reported. A total of 45 cases of APL with t(15,17)/PML-RARα were diagnosed at Harbor-UCLA Medical Center from year 2006 to 2015. Among them, only two cases were positive for HLA-DR by flow cytometry immunophenotyping. Here we describe the clinical, morphologic, immunophenotypic, and cytogenetic features of these two cases.
Collapse
Affiliation(s)
- Alejandro S Mendoza
- Department of Pathology, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502, USA
| | - Xin Qing
- Department of Pathology, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502, USA.
| | - Maria Dungo
- Department of Hematology and Oncology, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502, USA
| | - Joseph Lasky
- Department of Pediatrics, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502, USA
| | - Eduard Panosyan
- Department of Pediatrics, Harbor-UCLA Medical Center, 1000 West Carson Street, Torrance, CA 90502, USA
| | - Junchao Cai
- Terasaki Research Institute, Los Angeles, CA, USA.
| |
Collapse
|
4
|
Immunophenotypes and immune markers associated with acute promyelocytic leukemia prognosis. DISEASE MARKERS 2014; 2014:421906. [PMID: 25045197 PMCID: PMC4089198 DOI: 10.1155/2014/421906] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Revised: 05/08/2014] [Accepted: 05/30/2014] [Indexed: 12/28/2022]
Abstract
CD2+, CD34+, and CD56+ immunophenotypes are associated with poor prognoses of acute promyelocytic leukemia (APL). The present study aimed to explore the role of APL immunophenotypes and immune markers as prognostic predictors on clinical outcomes. A total of 132 patients with de novo APL were retrospectively analyzed. Immunophenotypes were determined by flow cytometry. Clinical features, complete remission (CR), relapse, and five-year overall survival (OS) rate were assessed and subjected to multivariate analyses. The CD13+CD33+HLA-DR-CD34− immunophenotype was commonly observed in patients with APL. Positive rates for other APL immune markers including cMPO, CD117, CD64, and CD9 were 68.7%, 26%, 78.4%, and 96.6%, respectively. When compared with patients with CD2− APL, patients with CD2+ APL had a significantly higher incidence of early death (50% versus 15.7%; P = 0.016), lower CR rate (50% versus 91.1%; P = 0.042), and lower five-year OS rate (41.7% versus 74.2%; P = 0.018). White blood cell (WBC) count before treatment was found to be the only independent risk factor of early death, CR failure, and five-year mortality rate. Flow cytometric immunophenotype analysis can facilitate prompt APL diagnosis. Multivariate analysis has demonstrated that WBC count before treatment is the only known independent risk factor that predicts prognosis for APL in this study population.
Collapse
|
5
|
Ahmad EI, Akl HK, Hashem ME, Elgohary TAM. The biological characteristics of adult CD34+ acute promyelocytic leukemia. Med Oncol 2011; 29:1119-26. [PMID: 21399995 DOI: 10.1007/s12032-011-9895-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2011] [Accepted: 03/01/2011] [Indexed: 11/27/2022]
Abstract
We aimed to explore the expression of CD34 and its impact on the disease outcome in patients with APL. The study comprised 40 de novo APL patients. Diagnostic tools included peripheral blood and bone marrow morphology and cytochemistry, immunophenotyping, cytogenetic studies, and PML/RARα fusion gene detection using RT-PCR. CD34 was expressed in 13 (32.5%) of cases with higher expression in M3v compared to M3 subtype. All M3v cases were CD34+, while only 7.4% of M3 cases were CD34+. CD34+ cases were associated with significant higher white blood cell count and peripheral blood promyelocytes. No significant association was found between PML/RAR-α isoform and molecular remission. CD34+ expression was significantly associated with decreased incidence of molecular remission and increased incidence of early death. The overall survival of patients with WBC count >11 × 103/μl was inferior to patients with WBC count <11 × 103/μl, but no significant differences were observed in overall survival between CD34- and CD34+ or between bcr1 and bcr3 groups. Immunophenotypic analysis for CD34 could distinguish an APL subset with different biological characteristics and adverse prognostic outcome.
Collapse
MESH Headings
- Adolescent
- Adult
- Aged
- Antigens, CD34/metabolism
- Female
- Flow Cytometry
- Humans
- Immunophenotyping
- Leukemia, Promyelocytic, Acute/classification
- Leukemia, Promyelocytic, Acute/metabolism
- Leukemia, Promyelocytic, Acute/mortality
- Leukemia, Promyelocytic, Acute/therapy
- Male
- Middle Aged
- Oncogene Proteins, Fusion/genetics
- Protein Isoforms
- Remission Induction
- Survival Rate
- Treatment Outcome
- Young Adult
Collapse
Affiliation(s)
- Ebtesam Ibrahim Ahmad
- Clinical Pathology Department, Faculty of Medicine, Zagazig University, Sharqyiah Governorate, Zagazig 44519, Egypt.
| | | | | | | |
Collapse
|
6
|
Ravella PM, Liu D, Kojima K, Weisberger J, Miura O, Kuyama J, Au W, Seiter K. Acute promyelocytic leukemia with tetraploid karyotype: first report in the Western hemisphere and update of previous reports. Leuk Res 2011; 35:e93-5. [PMID: 21353702 DOI: 10.1016/j.leukres.2011.01.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2011] [Revised: 01/12/2011] [Accepted: 01/24/2011] [Indexed: 11/25/2022]
|
7
|
Abdelhaleem M. Frequent but nonrandom expression of lymphoid markers on de novo childhood acute myeloid leukemia. Exp Mol Pathol 2007; 83:259-63. [PMID: 17662713 DOI: 10.1016/j.yexmp.2007.05.007] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2006] [Revised: 05/25/2007] [Accepted: 05/25/2007] [Indexed: 11/29/2022]
Abstract
Lymphoid marker expression in 59 cases of de novo childhood acute myeloid leukemia (AML) was as follows: CD2 (15.5%), CD4 (73.8%), CD7 (25.8%), CD19 (22%) and CD56 (28.9%). Individual marker expression, as well as co-expression with other lymphoid markers, could be correlated with the FAB subtype of leukemia and the presence and type of certain leukemia fusion gene transcripts. The data showed that the expression of lymphoid markers in childhood de novo AML was common but nonrandom and was likely a reflection of the biological differences between various types of leukemia.
Collapse
Affiliation(s)
- Mohamed Abdelhaleem
- Division of Haematopathology, Department of Paediatric Laboratory Medicine, Hospital for Sick Children, Toronto, Canada.
| |
Collapse
|
8
|
Current Awareness in Hematological Oncology. Hematol Oncol 2006. [DOI: 10.1002/hon.752] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|